As part of a project for the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, Office of Disability, Aging, and Long-Term Care Policy, Mathematica produced report examining the use of evidence-based medications, psychosocial services,...

Medicaid beneficiaries with schizophrenia and bipolar disorder require a range of services and supports. This descriptive study used 2007 Medicaid claims data from 21 states and the District of Columbia to examine the extent to which this population received guideline-concordant medications,...

This study found the use of injectable antipsychotics varied substantially among state Medicaid programs. African Americans received a disproportionate share in many states.

This study examines whether medication continuity among Medicaid beneficiaries with schizophrenia and bipolar disorder was associated with medication utilization management practices (prior authorization, copayment amounts, and refill and pill quantity limits); managed care enrollment; and other...

This study found the use of injectable antipsychotics varied substantially among state Medicaid programs. African Americans received a disproportionate share in many states.

This study examines whether medication continuity among Medicaid beneficiaries with schizophrenia and bipolar disorder was associated with medication utilization management practices (prior authorization, copayment amounts, and refill and pill quantity limits); managed care enrollment; and other...

This study used Medicaid Analytic eXtract (MAX) files to develop national estimates of Medicaid substance abuse (SA) treatment spending, as well as estimates of state spending in 18 states with predominantly fee-for-service coverage of SA treatment. Nationally, medical expenditures to treat SA...